What is the equity of Immunome this year?
Immunome has equity of 119.88 M USD this year.
Immunome Equity 2024
Immunome Equity
119.88 M USD
Ticker
IMNM
ISIN
US45257U1088
WKN
A2QD9D
In 2024, Immunome's equity was 119.88 M USD, a 620.01% increase from the 16.65 M USD equity in the previous year.
Immunome Aktienanalyse
What does Immunome do?
Immunome Inc was founded in 2020 and is based in Pennsylvania, USA. The company specializes in researching and developing therapeutic antibodies and vaccines. Its goal is to develop innovative drugs for the treatment of cancer, infectious diseases, and autoimmune diseases. The history of Immunome Inc began with the founding by a group of scientists and entrepreneurs who combined their expertise and experience in the field of immunology and biotechnology. Their goal was to build a company capable of conducting groundbreaking research and developing new therapies that offer improved chances of recovery. The business model is based on the discovery and development of monoclonal antibodies that have high specificity and effectiveness against specific target molecules. The strategy is to focus on new approaches to identify target molecules in order to develop drugs that specifically target the causes of diseases. Immunome Inc specializes in various areas: cancer, infectious diseases, and autoimmune diseases. Within these areas, the company focuses on identifying target molecules and developing monoclonal antibodies and vaccines that act specifically against these molecules. Products offered by Immunome Inc include monoclonal antibodies against various types of cancer such as breast cancer, prostate cancer, and lung cancer. These antibodies are currently being tested in clinical trials and show promising results. The company also offers a range of vaccines against various infectious diseases, including adaptable influenza vaccines and vaccines against the Ebola virus. In addition, Immunome Inc places great importance on the development of therapies for autoimmune diseases. This includes, for example, the discovery of autoantibodies that selectively balance the immune system and thus can control autoimmune diseases. In summary, Immunome Inc is an innovative biotech company specializing in the development and commercialization of monoclonal antibodies and vaccines against cancer, infectious diseases, and autoimmune diseases. Through its groundbreaking research, the company has the potential to save lives and contribute to the cure of diseases. Immunome ist eines der beliebtesten Unternehmen auf Eulerpool.com.Equity Details
Analyzing Immunome's Equity
Immunome's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Immunome's equity is essential for assessing its financial health, stability, and value to shareholders.
Year-to-Year Comparison
Evaluating Immunome's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.
Impact on Investments
Immunome's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.
Interpreting Equity Fluctuations
Fluctuations in Immunome’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.
Frequently Asked Questions about Immunome stock
What was the equity of Immunome compared to the previous year?
The equity of Immunome has increased/decreased by 620.01% increased compared to the previous year.
What impact does a high equity have on investors of Immunome?
A high equity is advantageous for investors of Immunome as it is an indicator of the company's financial stability and its ability to manage risks and challenges.
What impact does low equity have on investors of Immunome?
A low equity can be a risk for investors of Immunome, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.
How does an increase in equity of Immunome affect the company?
An increase in equity of Immunome can strengthen the company's financial position and improve its ability to make investments in the future.
How does a reduction in the equity of Immunome affect the company?
A reduction in equity of Immunome can affect the financial situation of the company and lead to a higher dependence on debt capital.
What are some factors that influence the equity of Immunome?
Some factors that can affect the equity of Immunome include profits, dividend payments, capital increases, and acquisitions.
Why is the equity of Immunome so important for investors?
The equity of Immunome is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.
What strategic measures can Immunome take to change the equity?
To change equity, Immunome can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.
How much dividend does Immunome pay?
Over the past 12 months, Immunome paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Immunome is expected to pay a dividend of 0 USD.
What is the dividend yield of Immunome?
The current dividend yield of Immunome is .
When does Immunome pay dividends?
Immunome pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Immunome?
Immunome paid dividends every year for the past 0 years.
What is the dividend of Immunome?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Immunome located?
Immunome is assigned to the 'Health' sector.
Wann musste ich die Aktien von Immunome kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Immunome from 10/25/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/25/2024.
When did Immunome pay the last dividend?
The last dividend was paid out on 10/25/2024.
What was the dividend of Immunome in the year 2023?
In the year 2023, Immunome distributed 0 USD as dividends.
In which currency does Immunome pay out the dividend?
The dividends of Immunome are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Immunome
Our stock analysis for Immunome Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Immunome Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
